Bicycle Therapeutics (BCYC) Current Deferred Revenue (2018 - 2026)

Bicycle Therapeutics (BCYC) has 9 years of Current Deferred Revenue data on file, last reported at $2.9 million in Q2 2026.

• Quarterly Current Deferred Revenue fell 80.31% year-over-year to $2.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $2.9 million (down 80.31% YoY) and the FY2025 annual result came in at $3.0 million, down 97.09% from the prior year.
• Current Deferred Revenue advanced to $2.9 million in Q2 2026, from $2.8 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $135.2 million in Q4 2023 to a low of $1.2 million in Q2 2022.
• A 5-year average of $24.7 million and a median of $12.4 million in 2025 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2023 — Current Deferred Revenue jumped 1726.95% — and 2025, when it slumped 97.09%.
• Tracing BCYC's Current Deferred Revenue over 5 years: stood at $7.4 million in 2022, then jumped by 1726.95% to $135.2 million in 2023, then declined by 24.81% to $101.7 million in 2024, then tumbled by 97.09% to $3.0 million in 2025, then retreated by 2.77% to $2.9 million in 2026.
• The last three Current Deferred Revenue figures came in at $2.9 million (Q2 2026), $2.8 million (Q1 2026), and $3.0 million (Q4 2025), per Business Quant data.